Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II adjuvant carboplatin-paclitaxel after extended-field chemoradiation for locally advanced cervical cancer with para-aortic node involvement
2018-001752-35Phase 2Completed
- Sponsor
- Centre Oscar Lambret
- Start
- Jun 2019
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carboplatin and paclitaxel in Cervical Cancer (CC), sponsored by Centre Oscar Lambret. Primary endpoint: Progression-free survival at 2 years. Started Jun 2019; status: completed.
02
Drugs
carboplatinpaclitaxel
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on 2018-001752-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001752-35.